GE HealthCare (NASDAQ:GEHC), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $34.6 billion, announced Monday a Distribution and Services Agreement with CardioNavix, a division of CDL Nuclear Technologies, to expand the availability of its cardiac PET imaging agent Flyrcado.
The collaboration aims to bring Flyrcado to patients nationwide, particularly in private cardiology practices and outpatient settings. CardioNavix, which supports approximately 220,000 cardiac PET procedures annually through nearly 225 U.S. customer sites, will become the first distributor to bring Flyrcado to private practice cardiology. This expansion aligns with GE HealthCare’s strong market position, supported by annual revenues of nearly $20 billion and a healthy gross profit margin of 41.6%.
Flyrcado is used for positron emission tomography myocardial perfusion imaging to evaluate patients with known or suspected coronary artery disease. In the Phase III AURORA trial, the imaging agent demonstrated higher diagnostic efficacy compared to SPECT myocardial perfusion imaging.
Initial rollout of Flyrcado through this agreement will begin in late 2025, with broader expansion planned throughout 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.